Global Vulvovaginal Candidiasis Treatment Market Overview
According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.
The vagina and the tissues close to the vulva's opening are both impacted by vulvovaginal candidiasis, a yeast infection. Candida species are the culprit behind it. Intense itching, inflammation, a thick, white discharge, and other signs of the illness are present. A single dose of the antifungal medication or the use of antifungal creams can cure a mild infection, but more extensive infections need more time-consuming therapy. The size of the global market for vulvovaginal candidiasis treatments is anticipated to increase. An NCBI article claims that VVC is a frequent virus in women that affects millions of women annually all over the world. Rising illness burden, a strong growing pipeline with recent approvals of disease management medicines, and the introduction of novel pharmaceuticals like BREXAFEMME and VIVJOA are some of the main reasons propelling market growth.The rising prevalence of VVC disease, the approval of novel medications that can address unmet needs, and initiatives by the government and non-profit groups to raise awareness are some of the major drivers of business growth.
Impact of COVID-19 on the Global Vulvovaginal Candidiasis Treatment Market
The global expansion of the new coronavirus has had a minor influence on the market for treating vulvovaginal candidiasis. Due to the increased prevalence of candidiasis among COVID-19 patients, there was a considerable demand for medications to treat vulvovaginal candidiasis. This is due to an increase in bloodstream infections and infections related with healthcare, particularly in patients who have been hospitalized to hospitals. The market for vulvovaginal candidiasis has quickly rebounded as a result of all these factors, and it is expected to keep expanding.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Drug Class, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Grupo Ferrer International S.A., Mycovia Pharmaceuticals, Inc., Pfizer, Inc., Scynexis, Inc. |
Global Vulvovaginal Candidiasis Treatment Market Segmentation:
1. By Drug Class:
- Clotrimazole
- Fluconazole
- Ketoconazole
- Nystatin
- Terbinafine
- Terconazole
- Others
2. By Route of Administration:
3. By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
4. By Region:
- Asia-Pacific
- Europe
- Middle East & Africa
- North America
- South America
Key Topics Covered in the Report:- Size of Global Vulvovaginal Candidiasis Treatment Market (FY’2019-FY’2032)
- Overview of Global Vulvovaginal Candidiasis Treatment Market
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Drug Class (Clotrimazole, Fluconazole, Ketoconazole, Nystatin, Terbinafine, Terconazole, Others)
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Route of Administration (Intravenous, Oral, Topical)
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
- Statistical Snap of Global Vulvovaginal Candidiasis Treatment Market
- Growth Analysis of Global Vulvovaginal Candidiasis Treatment Market
- Problems and Challenges in Global Vulvovaginal Candidiasis Treatment Market
- Competitive Landscape in the Global Vulvovaginal Candidiasis Treatment Market
- Impact of COVID-19 and Demonetization on Global Vulvovaginal Candidiasis Treatment Market
- Details on Recent Investment in Global Vulvovaginal Candidiasis Treatment Market
- Competitive Analysis of Global Vulvovaginal Candidiasis Treatment Market
- Major Players in the Global Vulvovaginal Candidiasis Treatment Market
- SWOT Analysis of Global Vulvovaginal Candidiasis Treatment Market
- Global Vulvovaginal Candidiasis Treatment Market Future Outlook and Projections (FY’2019-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Vulvovaginal Candidiasis Treatment Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Vulvovaginal Candidiasis Treatment Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vulvovaginal Candidiasis Treatment Market
7. Global Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2019-2032 (USD Million)
7.1 Clotrimazole
7.2 Fluconazole
7.3 Ketoconazole
7.4 Nystatin
7.5 Terbinafine
7.6 Terconazole
7.7 Others
8. Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2019-2032 (USD Million)
8.1 Intravenous
8.2 Oral
8.3 Topical
9. Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2019-2032 (USD Million)
9.1 Hospital Pharmacy
9.2 Online Pharmacy
9.3 Retail Pharmacy
10. Global Vulvovaginal Candidiasis TreatmentMarket, By Region, 2019-2032 (USD Million)
10.1 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2019-2025)
10.2 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2026-2032)
10.3 Asia-Pacific
10.3.1 Australia
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 Europe
10.4.1 France
10.4.2 Germany
10.4.3 Italy
10.4.4 Spain
10.4.5 United Kingdom
10.4.6 Rest of Europe
10.5 Middle East & Africa
10.5.1 Kingdom of Saudi Arabia
10.5.2 United Arab Emirates
10.5.3 Rest of Middle East & Africa
10.6 North America
10.6.1 Canada
10.6.2 Mexico
10.6.3 United States
10.7 Latin America
10.7.1 Argentina
10.7.2 Brazil
10.7.3 Rest of South America
11. Company Profiles
11.1 Astellas Pharma Inc.
11.1.1 Company details
11.1.2 Financial outlook
11.1.3 Product summary
11.1.4 Recent developments
11.2 Basilea Pharmaceutica Ltd.
11.2.1 Company details
11.2.2 Financial outlook
11.2.3 Product summary
11.2.4 Recent developments
11.3 Bayer AG
11.3.1 Company details
11.3.2 Financial outlook
11.3.3 Product summary
11.3.4 Recent developments
11.4 Bristol-Myers Squibb Company
11.4.1 Company details
11.4.2 Financial outlook
11.4.3 Product summary
11.4.4 Recent developments
11.5 Cadila Pharmaceuticals
11.5.1 Company details
11.5.2 Financial outlook
11.5.3 Product summary
11.5.4 Recent developments
11.6 Grupo Ferrer International S.A.
11.6.1 Company details
11.6.2 Financial outlook
11.6.3 Product summary
11.6.4 Recent developments
11.7 Mycovia Pharmaceuticals, Inc.
11.7.1 Company details
11.7.2 Financial outlook
11.7.3 Product summary
11.7.4 Recent developments
11.8 Pfizer, Inc.
11.8.1 Company details
11.8.2 Financial outlook
11.8.3 Product summary
11.8.4 Recent developments
11.9 Scynexis, Inc.
11.9.1 Company details
11.9.2 Financial outlook
11.9.3 Product summary
11.9.4 Recent developments
12. List of Abbreviations
13. Reference Links
14. Conclusion
15. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
